Aspen Pharmacare
| Aspen Pharmacare
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | ZAE000066692 |
| founding | 1850 |
| Seat | Durban , South Africa |
| management | Stephen Saad |
| Branch | Biotechnology and pharmacy |
| Website | aspenpharma.com |
Aspen Pharmacare is a South African pharmaceutical company .
The company is the largest pharmaceutical company originating from Africa. The company specializes primarily in generics and in the treatment of HIV / AIDS and tuberculosis . The company was founded in 1850. In 2011, Aspen acquired the Bad Oldesloe plant from GlaxoSmithKline .
In 2016, the company was fined more than € 5.2 million by the Italian antitrust authorities for suspending the supply of several cancer drugs, such as melphalan and chlorambucil , for tactical reasons in order to increase prices by up to 1,500 percent easier to enforce. Aspen had recently acquired the license for these drugs, whose patent protection has already expired, from GlaxoSmithKline. In France, 3 patients died after receiving cyclophosphamide as an alternative drug for melphalan. The EU Commission also started investigations against the company in 2017 on suspicion of exorbitant prices. In its own investigation, the Competition and Markets Authority, the UK's competition authority , found that Aspen had formed an illegal cartel with 2 other manufacturers to increase the price of fludrocortisone by up to 1800%. Aspen has admitted to this antitrust agreement and paid £ 8 million in compensation to the NHS .
Web links
- aspenpharma.com
- Reuters.com: Aspen under EU antitrust spotlight over excessive cancer drug prices, May 15, 2017
Individual evidence
- ↑ Bloomberg: Aspen offers $ 1.24 Billion for Sigma Pharmaceuticals
- ↑ Glaxo sells his work in Oldeslo , at www.abendblatt.de , accessed on January 3, 2019
- ^ Ed Silverman: Drug maker fined for shorting supplies of cancer drugs in order to raise prices , STAT News , October 17, 2016
- ↑ Autorità Garante della concorrenza e del Mercato: decision of the meeting of 29 September 2016 , 2016 (pdf)
- ↑ Sarah Boseley: Drugs firms are accused of putting cancer patients at risk overprice hikes , The Guardian , 28 January 2017
- ↑ EU Commission investigates Aspen Pharma because of exorbitant prices , Deutsche Apotheker-Zeitung , May 15, 2017
- ↑ European Commission: Antitrust: Commission opens formal investigation into Aspen Pharma's pricing practices for cancer medicines , Press release, May 15, 2017
- ↑ Competition and Markets Authority: 3 drug firms accused of illegal market sharing , press release, October 3, 2019
- ↑ Aspen found guilty of antitrust activities in the UK , The Pharma Letter , August 14, 2019
- ↑ Competition and Markets Authority: CMA pharma probe secures £ 8m for the NHS , press release, August 14, 2019